Wide Ranks

GANX

Gain Therapeutics, Inc.

1.74

Top Statistics
Market Cap 46 M Forward PE -2.03 Revenue Growth 0.00 %
Current Ratio 2.84 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.42 Enterprise / Revenue Price To Sales Trailing12 Months Infinity
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 16 M Total Cash Per Share 0.6630 Total Debt 807570
Total Debt To Equity 6.85 Current Ratio 2.84 Book Value Per Share 0.7760
All Measures
Short Ratio 165.00 % Message Board Id finmb_554488027 Shares Short Prior Month 654274
Return On Equity -1.89 City Bethesda Uuid b010f87c-2d85-33b5-99a7-679af46af6c6
Previous Close 1.73 First Trade Date Epoch Utc 1 B Book Value 0.7760
Beta 0.3360 Total Debt 807570 Volume 258428
Price To Book 2.24 Fifty Two Week Low 0.8900 Total Cash Per Share 0.6630
Shares Short Previous Month Date 1 B Target Median Price 8.00 Max Age 86400
Recommendation Mean 1.40 Sand P52 Week Change 0.3133 Target Mean Price 7.40
Net Income To Common -21599504 Short Percent Of Float 0.0271 Implied Shares Outstanding 26 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 260330
Average Volume10days 260330 Total Cash 16 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0509 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 1.73 Target Low Price 5.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.08 Open 1.79
Free Cashflow -10058968 State MD Dividend Yield 0.00 %
Return On Assets -0.7296 Time Zone Short Name EST Trailing Eps -1.07
Day Low 1.71 Address1 4800 Montgomery Lane Shares Outstanding 26 M
Price Hint 4 Target High Price 10.00 Website https://www.gaintherapeutics.com
52 Week Change -0.1869 Average Volume 391950 Forward Eps -0.8900
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 264.40 %
Is_sp_500 False Regular Market Day High 1.86 Profit Margins 0.00 %
Debt To Equity 6.85 Fifty Two Week High 5.33 Day High 1.86
Shares Short 658341 Regular Market Open 1.79 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0258
Operating Cashflow -18970080 Currency USD Time Zone Full Name America/New_York
Market Cap 46 M Is_nasdaq_100 False Zip 20814
Quote Type EQUITY Industry Biotechnology Long Name Gain Therapeutics, Inc.
Regular Market Day Low 1.71 Held Percent Institutions 0.0796 Current Price 1.74
Address2 Suite 220 Enterprise To Ebitda -1.42 Financial Currency USD
Current Ratio 2.84 Industry Disp Biotechnology Number Of Analyst Opinions 5
Country United States Float Shares 24 M Two Hundred Day Average 2.36
Enterprise Value 30 M Price To Sales Trailing12 Months Infinity Forward PE -2.03
Regular Market Volume 258428 Ebitda -21823828 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas.

Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials.

It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors.

The company was founded in 2017 and is headquartered in Bethesda, Maryland.